The beneficial effect of vanillin on 6-hydroxydopamine rat model of Parkinson's disease

Restor Neurol Neurosci. 2020;38(5):369-373. doi: 10.3233/RNN-201028.

Abstract

Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder that is related to neuroinflammation. Vanillin, which possesses both antioxidant, and anti-inflammatory properties, can be a candidate for neuroprotection in PD.

Objective: This study was aimed to investigate the effects of vanillin on the 6-hydroxydopamine (6-OHDA) rodent model of PD.

Methods: Male Wistar rats were administrated intraperitoneal (i.p) or oral vanillin at a dose of 20 mg/kg/day for 7 days that was started at three days before or seven days after intracerebral injection of 6-OHDA. The 6-OHDA-induced lesions were assessed behaviorally using the apomorphine rotation test, neurochemically via measuring striatal dopamine concentrations, and through immunohistochemistry.

Results: Both oral and IP vanillin at three days before or seven days after 6-OHDA lesioning exhbited significantly lower tight contralateral rotations upon apomorphine challenge, and higher striatal dopamine concentrations.

Conclusions: Vanillin seems to offer protective properties against 6-OHDA lesion via preserving striatal dopamine levels.

Keywords: 6-OHDA; Parkinson’s disease; Vanillin; dopamine; immunostaining; striatum.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Behavior, Animal / drug effects
  • Behavior, Animal / physiology
  • Benzaldehydes / administration & dosage
  • Benzaldehydes / pharmacology*
  • Corpus Striatum / drug effects*
  • Corpus Striatum / metabolism*
  • Disease Models, Animal
  • Dopamine / metabolism*
  • Immunohistochemistry
  • Male
  • Neuroprotective Agents / pharmacology*
  • Oxidopamine / administration & dosage*
  • Parkinson Disease* / drug therapy
  • Parkinson Disease* / metabolism
  • Parkinson Disease* / pathology
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / drug therapy
  • Parkinson Disease, Secondary / metabolism
  • Parkinson Disease, Secondary / pathology
  • Rats
  • Rats, Wistar

Substances

  • Benzaldehydes
  • Neuroprotective Agents
  • Oxidopamine
  • vanillin
  • Dopamine